Research Analysts Issue Forecasts for KTTA FY2026 Earnings

Pasithea Therapeutics Corp. (NASDAQ:KTTA) – Equities researchers at HC Wainwright dropped their FY2026 EPS estimates for shares of Pasithea Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Nik now forecasts that the company will earn ($1.86) per share for the year, down from their prior forecast of ($0.68). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. HC Wainwright also issued estimates for Pasithea Therapeutics’ FY2027 earnings at ($2.10) EPS and FY2028 earnings at ($2.30) EPS.

A number of other analysts have also recently commented on KTTA. Weiss Ratings reissued a “sell (e+)” rating on shares of Pasithea Therapeutics in a research report on Friday, March 27th. Wall Street Zen upgraded Pasithea Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, January 18th. Finally, Zacks Research raised Pasithea Therapeutics to a “hold” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pasithea Therapeutics has an average rating of “Hold” and a consensus price target of $3.00.

Pasithea Therapeutics Stock Performance

Shares of NASDAQ KTTA opened at $0.77 on Friday. The company has a 50 day simple moving average of $0.80 and a two-hundred day simple moving average of $0.85. Pasithea Therapeutics has a fifty-two week low of $0.28 and a fifty-two week high of $3.79. The company has a market capitalization of $19.20 million, a price-to-earnings ratio of -0.22 and a beta of 0.25.

Pasithea Therapeutics (NASDAQ:KTTA) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.71).

Institutional Trading of Pasithea Therapeutics

Large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC increased its holdings in Pasithea Therapeutics by 43.7% during the third quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock valued at $48,000 after buying an additional 20,483 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Pasithea Therapeutics by 113.9% during the 4th quarter. Geode Capital Management LLC now owns 54,495 shares of the company’s stock worth $70,000 after acquiring an additional 29,020 shares during the last quarter. Jane Street Group LLC grew its position in shares of Pasithea Therapeutics by 137.0% during the 4th quarter. Jane Street Group LLC now owns 59,372 shares of the company’s stock valued at $77,000 after acquiring an additional 34,319 shares during the period. Two Sigma Investments LP bought a new stake in shares of Pasithea Therapeutics during the 3rd quarter valued at $26,000. Finally, AdvisorShares Investments LLC increased its stake in shares of Pasithea Therapeutics by 18.2% in the 4th quarter. AdvisorShares Investments LLC now owns 304,721 shares of the company’s stock worth $393,000 after purchasing an additional 47,025 shares in the last quarter. 23.92% of the stock is currently owned by institutional investors.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.